Premium accounts now available! Sign up and create a premium account. Read more Close

Sign in

Sign in to personalize your content feed, follow keywords and sources you care about, bookmark content you like, and join the conversation by sharing your recommendations and comments.

Sign in with LinkedIn Sign in with Google

You can also sign in with your account. Don't have an account yet? Sign up

Your cookie settings

This site uses cookies. Some cookies are essential to make the site work and others help us to improve our services. Read more about cookies in our Privacy policy.

Choose your cookie preferences:

Advertisement

Image

[Articles] Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial

Journal content Created on 06 Nov 2026 The Lancet Oncology

Jian Zhang, Yehui Shi, Qingyuan Zhang, Yiqun Du, Yanchun Meng, Yongsheng Wang, Qiao Cheng, Xin Chen, Zhihua Li, Yongmei Yin, Jie Dong, Juan Zhang, Feifei Wang, Yankui Ou, Petra Rietschel, Claudia-Nanette Gann, Ilhan Celik, Jiong Wu

Advertisement

Stats

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Do you recommend this? Please sign in. Yes No

Recommended

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement